- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03997786
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
February 15, 2024 updated by: Sun Pharmaceutical Industries Limited
A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE).
The initial PK analysis is first done in adolescent subjects (12 to <18 years) before initiating the PK study in younger cohort (6 to <12 years)
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
130
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Head, Clinical development
- Phone Number: 5689 91 2266455645
- Email: Clinical.Trial@sunpharma.com
Study Locations
-
-
-
Budapest, Hungary, H-1033
- Not yet recruiting
- Site 63
-
Budapest, Hungary, H-1036
- Recruiting
- Site 62
-
Debrecen, Hungary, H-4032
- Recruiting
- Site 61
-
Kaposvar, Hungary, H-7400
- Recruiting
- Site 64
-
Szeged, Hungary, 6720
- Withdrawn
- Site 28
-
-
-
-
-
Ahmedabad, India, 380015
- Not yet recruiting
- Site 70
-
Ahmedabad, India, 380009
- Recruiting
- Site 79
-
Chennai, India, 600004
- Not yet recruiting
- Site 78
-
Kolkata, India, 700058
- Not yet recruiting
- Site 75
-
Kolkata, India, 700073
- Not yet recruiting
- Site 76
-
Lucknow, India, 226005
- Recruiting
- Site 71
-
Pune, India, 411001
- Not yet recruiting
- Site 73
-
Surat, India, 395010
- Not yet recruiting
- Site 77
-
Surat, India, 395002
- Recruiting
- Site 74
-
Warangal, India, 506002
- Recruiting
- Site 80
-
-
-
-
-
Bialystok, Poland, 15-453
- Recruiting
- Site 57
-
Gdańsk, Poland, 80-214
- Not yet recruiting
- Site 55
-
Katowice, Poland, 40-611
- Recruiting
- Site 51
-
Lodz, Poland, 90-265
- Recruiting
- Site 54
-
Lodz, Poland, 90-436
- Recruiting
- Site 56
-
Lublin, Poland, 20-573
- Recruiting
- Site 58
-
Ostrowiec Swietokrzyski, Poland, 27-400
- Recruiting
- Site 50
-
Sosnowiec, Poland, 41-200
- Recruiting
- Site 59
-
Szczecin, Poland, 70-332
- Recruiting
- Site 52
-
Warszawa, Poland, 02-507
- Recruiting
- Site 53
-
Wrocław, Poland, 50-566
- Withdrawn
- Site 40
-
Wrocław, Poland, 51-503
- Recruiting
- Site 39
-
Contact:
- Phone Number: 48 515 138 395
- Email: Mateusz.machay@dermmedica.pl
-
Wrocław, Poland, 51-685
- Recruiting
- Site 38
-
Contact:
- Phone Number: 48 607 375 354
- Email: zuzanna.pawlak@wromedica.pl
-
-
-
-
-
Bardejov, Slovakia, 8501
- Recruiting
- Site 92
-
Svidnik, Slovakia, 8901
- Recruiting
- Site 91
-
Trnava, Slovakia, 91775
- Not yet recruiting
- Site 90
-
-
-
-
-
Barcelona, Spain, 08041
- Not yet recruiting
- Site 41
-
Contact:
- Phone Number: +34 93 55 37 007
- Email: lpuig@hsp.santpau.es
-
Las Palmas De Gran Canaria, Spain, 35019
- Recruiting
- Site 47
-
Contact:
- Phone Number: +34636843487
- Email: anagrabasco@gmail.com
-
Madrid, Spain, 28041
- Withdrawn
- Site 42
-
Valencia, Spain, 46014
- Withdrawn
- Site 44
-
Valencia, Spain, 46940
- Withdrawn
- Site 45
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35244
- Withdrawn
- Site 23
-
-
California
-
Fountain Valley, California, United States, 92708
- Recruiting
- Site 1
-
Contact:
- Phone Number: 714-531-2966
- Email: vanessa.firstocdermatology@gmail.com
-
Thousand Oaks, California, United States, 91320
- Recruiting
- Site 2
-
Contact:
- Phone Number: 805-298-7021
- Email: clinicaltrials@calderm.net
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Withdrawn
- Site 4
-
Coral Gables, Florida, United States, 33146
- Withdrawn
- Site 24
-
Miami, Florida, United States, 33126
- Completed
- Site 20
-
Miami, Florida, United States, 33173
- Recruiting
- Site 7
-
Contact:
- Phone Number: 125 305-273-7998
- Email: v.diartt@skinresearchsf.com
-
Orlando, Florida, United States, 32819
- Withdrawn
- Site 12
-
-
Michigan
-
Bay City, Michigan, United States, 48706
- Withdrawn
- Site 5
-
Troy, Michigan, United States, 48084
- Withdrawn
- Site 16
-
-
Missouri
-
Saint Joseph, Missouri, United States, 64506
- Withdrawn
- Site 22
-
-
Texas
-
Dallas, Texas, United States, 75231
- Withdrawn
- Site 8
-
-
Utah
-
South Jordan, Utah, United States, 84095
- Withdrawn
- Site 10
-
-
Washington
-
Spokane, Washington, United States, 99202
- Completed
- Site 14
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject must be 6 to < 18 years of age, of either sex, of any race/ ethnicity, must weight greater than or equal to 15Kg.
- Diagnosis of predominantly plaque psoriasis for ≥6 months (as determined by subject interview and confirmation of diagnosis through physical examination by investigator).
- Moderate to severe psoriasis at baseline defined as: at least 10% Body Surface Area (BSA) involvement, PGA score ≥ 3, and PASI score ≥ 12
- Subject must be considered a candidate for systemic therapy, meaning psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy
- Subject is considered to be eligible according to tuberculosis (TB) screening criteria
- A maximum of 2 QuantiFERON tests will be allowed. A re-test is only permitted if the first is indeterminate; the result of the second test will then be used.
Exclusion Criteria:
- Subject has predominantly non-plaque forms of psoriasis specifically erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new-onset guttate psoriasis
- Subject has laboratory abnormalities at screening including any of the following: Alanine transaminase (ALT) or aspartate transaminase, (AST) ≥2X the upper limit of normal, Creatinine ≥1.5X the upper limit of normal serum direct bilirubin ≥ 1.5 mg/dL, white blood cell count < 3.0 x 103/μL, and any other laboratory abnormality, which, in the opinion of the Investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results
- Subject who is expected to require topical therapy, phototherapy, or additional systemic therapy for psoriasis during the trial
- Female subjects of childbearing potential who are pregnant, intend to become pregnant (within 6 months of completing the trial), or are lactating. (Sexually active adolescent girls will be required to use contraception)
- Subject with presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics within 2 weeks prior to Screening, or severe infection (e.g. pneumonia, cellulitis, bone or joint infections) requiring hospitalization or treatment with IV antibiotics within 8 weeks prior to Screening
- Positive human immunodeficiency virus (HIV) test result, hepatitis B surface (HBS) antigen, or hepatitis C virus (HCV) test result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Part A
Part A is a DOSE FINDING COMPONENT: OPEN LABEL PK lead-in and safety component
|
Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
(Weeks 16 to 52)
at every 12 weeks in open label fashion till 5 years (240 weeks).
(Weeks 0 to 16)
|
Experimental: Part B Part 1: Placebo and active comparator controlled study
|
Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
(Weeks 16 to 52)
at every 12 weeks in open label fashion till 5 years (240 weeks).
(Weeks 0 to 16)
(Weeks 0 to 16)
(Weeks 0 to 16)
(Weeks 16 to 52)
|
Experimental: Part B-1 and B-2: Randomized withdrawal and retreatment after relapse
|
Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
(Weeks 16 to 52)
at every 12 weeks in open label fashion till 5 years (240 weeks).
(Weeks 0 to 16)
(Weeks 0 to 16)
(Weeks 16 to 52)
|
No Intervention: Part B 3: Efficacy and Safety Follow-up
|
|
Experimental: Part C: LTE
|
Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
(Weeks 16 to 52)
at every 12 weeks in open label fashion till 5 years (240 weeks).
(Weeks 0 to 16)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A - Maximum Plasma Concentration
Time Frame: Day 3, 7 and 28 following first dose
|
Day 3, 7 and 28 following first dose
|
Part A - Area under the plasma concentration-time curve
Time Frame: Day 3, 7 and 28 following first dose
|
Day 3, 7 and 28 following first dose
|
Part A - Maximum Plasma Concentration
Time Frame: Weeks 4,8, and 12 following second dose
|
Weeks 4,8, and 12 following second dose
|
Part A - Area under the plasma concentration-time curve
Time Frame: Weeks 4,8, and 12 following second dose
|
Weeks 4,8, and 12 following second dose
|
Proportion of subjects with at least 75% improvement in the PASI response from baseline
Time Frame: Week 12
|
Week 12
|
Proportion of subjects with PGA of "clear" or "almost clear" with at least a 2 grade reduction from baseline
Time Frame: Week 12
|
Week 12
|
Number of subjects with adverse events
Time Frame: Week 52
|
Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects achieving Psoriasis Area & Severity Index (PASI) 50 from baseline
Time Frame: Week 12, 16, 28, 40, 52, 64, 76 and 88
|
Week 12, 16, 28, 40, 52, 64, 76 and 88
|
|
Proportion of subjects achieving Psoriasis Area & Severity Index (PASI) 90 from baseline
Time Frame: Week 12, 16, 28, 40, 52, 64, 76 and 88
|
Week 12, 16, 28, 40, 52, 64, 76 and 88
|
|
Proportion of subjects achieving Psoriasis Area & Severity Index (PASI) 100 from baseline
Time Frame: Week 12, 16, 28, 40, 52, 64, 76 and 88
|
Week 12, 16, 28, 40, 52, 64, 76 and 88
|
|
Proportion of subjects achieving PASI 75 and PGA score of "clear" or "almost clear" with at least a 2 grade reduction from baseline
Time Frame: Week 16, 28, 40, 52, 64, 76 and 88
|
Week 16, 28, 40, 52, 64, 76 and 88
|
|
Change in quality of life as measured by Children's Dermatology Life Quality Index (CDLQI)
Time Frame: Week 108
|
The CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's (aged 2-15 years) quality of life.
Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life.
The CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the children's life; 2-6 = small effect on the children's life; 7-12 = moderate effect on the children's life; 13-18 = very large effect on the children's life; 19-30 = extremely large effect on the children's life.
Higher scores indicate more impact on quality of life of children.
|
Week 108
|
Number of subjects with Adverse events
Time Frame: Week 108
|
Week 108
|
|
Immunogenicity - Anti-drug antibody status
Time Frame: Week 108
|
Week 108
|
|
Percent of subjects with severe infections
Time Frame: Week 108
|
defined as any infection meeting the regulatory definition of a serious adverse event, or any infection requiring IV antibiotics whether or not reported as a serious event as per the regulatory definition
|
Week 108
|
Percent of subjects with malignancies
Time Frame: Week 108
|
including non-melanoma and melanoma skin cancer, but excluding carcinoma in situ of the cervix
|
Week 108
|
Percent of subjects with confirmed major adverse cardiovascular events
Time Frame: Week 108
|
major adverse cardiovascular events
|
Week 108
|
Percent of subjects with drug- related hypersensitivity reactions
Time Frame: Week 108
|
e.g.
anaphylaxis, urticarial, angioedema, etc
|
Week 108
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relapse rates after withdrawal of treatment with tildrakizumab
Time Frame: Week 52
|
Week 52
|
Rebound rates after withdrawal of treatment with tildrakizumab
Time Frame: Week 52
|
Week 52
|
response to retreatment after relapse after withdrawal of treatment with tildrakizumab - Proportion of subjects with at least 75% improvement in the PASI response from baseline
Time Frame: Week 52
|
Week 52
|
response to retreatment after relapse after withdrawal of treatment with tildrakizumab - Proportion of subjects with PGA of "clear" or "almost clear" with at least a 2 grade reduction from baseline
Time Frame: Week 52
|
Week 52
|
Maintenance of response - Proportion of subjects with at least 75% improvement in the PASI response from baseline
Time Frame: Week 52
|
Week 52
|
Maintenance of response - Proportion of subjects with PGA of "clear" or "almost clear" with at least a 2 grade reduction from baseline
Time Frame: Week 52
|
Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2020
Primary Completion (Estimated)
May 23, 2031
Study Completion (Estimated)
July 23, 2031
Study Registration Dates
First Submitted
June 19, 2019
First Submitted That Met QC Criteria
June 24, 2019
First Posted (Actual)
June 25, 2019
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Etanercept
- Antibodies, Monoclonal
Other Study ID Numbers
- TILD-19-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate-to-severe Chronic Plaque Psoriasis
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingModerate to Severe Chronic Plaque PsoriasisChina
-
Novartis PharmaceuticalsActive, not recruitingModerate to Severe Chronic Plaque PsoriasisChina
-
AbbVie (prior sponsor, Abbott)IMS HealthCompletedModerate-to-severe Chronic Plaque Psoriasis
-
Genzyme, a Sanofi CompanyCompletedModerate to Severe Chronic Plaque PsoriasisUnited States
-
CelltrionRecruitingModerate to Severe Chronic Plaque PsoriasisEstonia
Clinical Trials on Tildrakizumab
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting
-
Almirall, S.A.Active, not recruitingPlaque PsoriasisGermany, Austria, Italy, Netherlands
-
Almirall, S.A.RecruitingGenital PsoriasisAustria
-
Sun Pharmaceutical Industries LimitedCompleted
-
Marcelo F. Di Carli, MD, FACCRecruiting
-
Sun Pharmaceutical Industries LimitedActive, not recruitingChronic Plaque Psoriasis | Moderate to Severe Nail PsoriasisUnited States, Australia
-
Almirall, S.A.Recruiting
-
Merck Sharp & Dohme LLCCompleted
-
Almirall, S.A.TerminatedPlaque PsoriasisPoland
-
Medical College of WisconsinActive, not recruitingHematologic MalignanciesUnited States